Details

Last Funding Type

Non-Equity Assistant

Industries

Biotechnology,Pet

Founded date

Sep 17, 2017

Number Of Employee

1 - 10

Operating Status

Active

Vetigenics creates novel immunotherapies to treat cancer and other chronic conditions in dogs without the debilitating side effects. Our fully canine phage display platform, enables rapid isolation of unique antibody fragments (scFvs) or CANIBODIES™ to any antigen based binding affinity, functionality and developability. CANIBODIES™ are entirely generated from naïve, canine germline genes, don't require costly, time-consuming caninization and can be readily engineered into mAbs, BiTEs or CAR-T therapies. As a result, our therapies are designed for precision efficacy and lack of immunogenicity, not possible with other discovery technologies. Vetigenics is advancing three internally developed antibody products into the clinic with our 1st in dog studies starting during 1Q21